Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 251265
Corporate User License Price USD 10500
Corporate User License Price INR 753795
Site License Price USD 7000
Site License Price INR 502530
Request a Quote

Report Title

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Review, H2 2016



Executive Summary

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)

The report reviews Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview 6

Therapeutics Development 7

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Products under Development by Stage of Development 7

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Products under Development by Therapy Area 8

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Products under Development by Indication 9

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Products under Development by Companies 12

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Companies Involved in Therapeutics Development 20

Crescendo Biologics Limited 20

Exicure, Inc. 21

Novartis AG 22

Teva Pharmaceutical Industries Ltd. 23

UCB S.A. 24

Vipergen ApS 25

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Drug Profiles 26

Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

bimekizumab-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CB-001-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

E-34935-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

E-35018-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

E-35762-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

E-36041-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Recombinant Protein to Inhibit IL-17A for Psoriasis-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Dormant Projects 36

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)-Featured News & Press Releases 37

Jun 10, 2016: UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis 37

Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016) 38

Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists 38

Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting 39

Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies 39

Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Crescendo Biologics Limited, H2 2016 20

Pipeline by Exicure, Inc., H2 2016 21

Pipeline by Novartis AG, H2 2016 22

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 23

Pipeline by UCB S.A., H2 2016 24

Pipeline by Vipergen ApS, H2 2016 25

Dormant Projects, H2 2016 36

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Crescendo Biologics Limited

Exicure, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

UCB S.A.

Vipergen ApS

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Therapeutic Products under Development, Key Players in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Therapeutics, Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Pipeline Overview, Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Pipeline, Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand